Malignant melanoma

References

• Schrdber MM, Bozzo PD, Moon TE. Malignant melanoma In southern Arizona: increasing incidence and sunlight as an etiologic factor. Arch Dermatol 1981: 117(1): 6–11
   PubMedGoogle Scholar
• Allen ER Malignant melanoma: spontaneous regression after pregnancy. Br Med J 1955: 2: 1067–70
   PubMedGoogle Scholar
• Stewart H. A case of malignant melanoma and pregnancy. Br Med J 1955: 1: 647–50
   PubMedGoogle Scholar
• Summer WC. Spontaneous regression of melanoma: case report. Cancer 1953: 6: 1040–3
   PubMed Web of Science ®Google Scholar
• Shiu MR, Schottenfeld D, Maclean B, et al. Adverse effect of pregnancy on melanoma: a reappraisal. Cancer 1976: 37(1): 181–7
   PubMed Web of Science ®Google Scholar
• Clark WH Jr, Reimer RR, Greene M, et al. Origin of familial malignant melanomas from heritable melanocytic lesions: the BK mole syndrome. Arch Dermatol 1978: 114(5): 732–8
   PubMedGoogle Scholar
• Greene MH, Clark WH Jr; Tucker MA, et al. Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature. (Letter) Lancet 1980: 2(8202): 1024
   PubMed Web of Science ®Google Scholar
• Relmer RR, Clark WH Jr, Greene MH, et al. Precursor lesions In familial melanoma: a new genetic preneoplastic syndrome. JAMA 1978: 239(8): 744–6
   PubMed Web of Science ®Google Scholar
• NIH Consensus Development Conference Summary. Precursors to malignant melanoma. JAMA 1984: 251(14): 1864–6
   PubMed Web of Science ®Google Scholar
• Reed RJ. The pathology of human cutaneous melanoma. In: Costanzi J. ed. Malignant melanoma. I. Boston: Martinus Nyhoff. 1983
   Google Scholar
• Helse H, Krementz ET. Survival experience of patients with malignant melanoma of the skin, 1950–957. Natl Cancer Inst Monogr 1961: 6: 69–84
   PubMedGoogle Scholar
• Bodenham DC. Basic principles of surgery: malignant melanoma. In: McCarthy WH. ed. Melanoma and skin cancer. Sydney. Australia: VCN Blight. 1972: 375–83
   Google Scholar
• Shaw HM, McGovem VJ, Milton GW, et al. The female superiority in survival in clinical stage II cutaneous malignant melanoma. Cancer 1982: 49(9): 1941–4
   PubMed Web of Science ®Google Scholar
• Rampen F. Malignant melanoma: sex differences in survival after evidence of distant metastasis. Br J Cancer 1980: 42(1): 52–7
   PubMed Web of Science ®Google Scholar
• Shaw HM. McGovern VJ, Milton GW, et al. Malignant melanoma: Influence of site of lesion and age of patient in the female superiority in survival. Cancer 1980: 46(12): 2731–5
   PubMed Web of Science ®Google Scholar
• Breslow A. Prognostic factore in the treatment of cutaneous melanoma. J Cutan Pathol 1979: 6(3): 208–12
   PubMed Web of Science ®Google Scholar
• Balch CM, Soong SJ, Milton GW, et al. A comparison of prognostic factors and surgical results In 1,786 patients with localized (stage I) melanoma treated In Alabama. USA. and New South Wales. Australia. Ann Surg 1982: 196(6): 677–84
   PubMed Web of Science ®Google Scholar
• Veroneal U, Adamus J, Bandiexa DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982: 49(11): 2420–30
   PubMed Web of Science ®Google Scholar
• Elias EG, Dldolkar MS, Goel IP, et al. A clinicopathologic study of prognostic factors in cutaneous malignant melanoma Surg Gynecol Obstet 1977: 144(3): 327–34
   PubMedGoogle Scholar
• Breslow A, Macht SD. Optimal size of resection margin for thin cutaneous melanoma. Surg Gynecol Obstet 1977: 145(5): 691–2
   PubMedGoogle Scholar
• Balch CM, Murad TM, Soong SJ, et al. Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer 1979: 43(3): 883–8
   PubMed Web of Science ®Google Scholar
• Elder DE, Guerry D 4th, Hdberger RM, et al. Optimal resection margin for cutaneous malignant melanoma. Plast Reconstr Surg 1983: 71(1): 66–72
   PubMed Web of Science ®Google Scholar
• Galomb FM. Discussion of two papers entitled “Optimal resection margin for cutaneous melanoma” and “Patients' perception of the cosmetic Impact of melanoma resection.” Plast Reconstr Surg 1983: 71 (7): 76–8
   Google Scholar
• W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma. Stage 1 melanoma of the skin: the problem of resection margins. Eur J Cancer 1980: 16(8): 1079–85
   PubMed Web of Science ®Google Scholar
• Southwick HW, Slaughter DP, Hinkamp JF, et al. The role of regional node dissection in the treatment of malignant melanoma. Arch Surg 1962: 85: 63–8
   PubMedGoogle Scholar
• Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma. D. Prognostic factors in patients with stage 1 (localized) melanoma. Surgery 1979: 86(2): 343–51
   PubMed Web of Science ®Google Scholar
• Mehnert JH, Heard JL. Staging of malignant melanoma by depth of Invasion. Am J Surg 1965: 110: 168–76
   PubMed Web of Science ®Google Scholar
• Blois MS, Sagebiel RW, Tattle MS, et al. Judging prognosis in malignant melanoma of the skin: a problem of inference over small data sets. Ann Suig 1983: 198(2): 200–6
   PubMed Web of Science ®Google Scholar
• McCarthy WH, Dobson AJ. Martyn AL, et al. Melanoma in New South Wales 1970–76: surgical therapy and survival. Aust NZ J Surg 1982: 52(4): 424–30
   PubMedGoogle Scholar
• Bagley FH, Cady B, Lee A, et al. Changes in clinical presentation and management of malignant melanoma. Cancer 1981: 47(9): 2126–34
   PubMed Web of Science ®Google Scholar
• Kapelanski DP, Block GE, Kaufman M. Characteristics of the primary lesion of malignant melanoma as a guide to prognosis and therapy. Ann Surg 1979: 189(2): 225–35
   PubMed Web of Science ®Google Scholar
• Fortner JG, Woodruff J, Schottenfeld D, et al. Biostatistical basis of elective node dissection for malignant melanoma. Ann Surg 1977: 186(1): 101–3
   PubMed Web of Science ®Google Scholar
• Goldsmith HS, Shah JP, Kim DH. Prognostic significance of lymph node dissection In the treatment of malignant melanoma. Cancer 1970: 26(3): 606–9
   PubMed Web of Science ®Google Scholar
• Sandeman TF. Treat or watch? An evaluation of elective treatment of clinically unlnvolved nodes in malignant melanoma. Med J Aust 1965: 1: 42
   PubMedGoogle Scholar
• Ghamrawi KA, Glennie JM. The value of radiotherapy in the management of malignant melanoma of the nasal cavity. J Laryngol Otol 1974: 88(1): 71–5
   PubMed Web of Science ®Google Scholar
• Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma: preliminary results. Cancer 1978: 41(31: 948–56
   PubMed Web of Science ®Google Scholar
• Stehlin J, Greeff P, de Ipolyi P, et al. Heat as an adjuvant in the treatment of advanced melanoma: an immune stimulant? Houston Med J 1988: 4: 61–81
   Google Scholar
• Mesykens F, Kopecky K, Costanzi J, et al. A randomized phase in trial of highdose vitamin A vs placebo for stage I malignant melanoma. (Abstr) Proc Am Soc Clin Oncol 1988: 7: 247
   Google Scholar
• Fletcher WS, Green S, Fletcher JR. et al. Evaluation of cisplatinum and DTIC combination chemotherapy in disseminated malignant melanoma. Proc Am Soc Clin Oncol 1986: 5: 131
   Google Scholar
• Glover D, Glick JH, Weller C. et al. WR-2721 and high-dose cisplatin: an active combination In the treatment of metastatic melanoma. J Clin Oncol 1987: 5(4): 574–8
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphoklne-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987: 316(15): 889–97
   PubMed Web of Science ®Google Scholar
• West WH, Tauer KW, Tannelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987: 316(15): 898–905
   PubMed Web of Science ®Google Scholar